Male Female Lec Seniority FINAL 1.10.10.xlsx - SSA Punjab

More documents

Recommendations

Info

01-10-2010Seniori Roster of Rosterps"o wk;Nops"o b?euokops"o b?euokofB:Z[esh dkPro Or Roaster Merit Date ofDate ofDirect ofBkw $ fgsk dk BkwiBw fwshft;akfB:[esh dhfB:[esh dhjkioh dhstyySnty No.;kXBRecruit PromottfwshDirect Point No. AppointmentfwshJoiningfwshizlHw e?Nkroh Cat Remarks1982 1206 i;o{g f;zx $ jouoB f;zx 28.5.59 ewo; - soZeh okjh Pro 18-12-1995 18.12.95 08-01-1996 8.1.96 rYxw iBob Gen CF 402 GEN1983 1207 fJepkb f;zx $ niw/o f;x 4.5.66 fJfsjk; - soZeh okjh Pro 18-12-1995 18.12.95 27-12-1995 27.12.95 Bwrgo ngr jlMDr iBob Gen1984 1208 r[ouoB f;zx $ rzrk f;zx 5.10.57 ewo; 1.4.85 soZeh okjh Pro 18-12-1995 18.12.95 04-01-1996 4.1.96 Bgqw BweI phH;hH BC1985 1209 ;abftzdo f;zx $ d[bk f;x 2.3.53 ewo; 20.5.88 soZeh okjh Pro 18-12-1995 18.12.95 13-01-1996 13.1.96 m`KU iProzpur phH;hH BC1986 1210 ;zs'a;a e[wko $ dhtkB uzd 17.9.54 nzro/ih 9$80 - soZeh okjh Pro 13-02-1996 13.2.96 07-05-2001 7.5.01 iProzpur klW iBob Gen1987 1211 pbtho f;x $ ni?p f;zx 23.12.56 fj;kp 2$96 12.10.80 soZeh okjh Pro 07-05-1996 7.5.96 21-09-1996 21.9.96 AmrgVH sMgrUr iBob Gen CF 403 GEN1988 1212 sob'uB f;x $ jouzd f;x 12.2.68 gzikph 2$96 soZeh okjh Pro 14-05-1996 14.5.96 17-07-1996 17.7.96 mwloBwl iBob Gen1989 777 r[oXkB f;zx $ fgnkok f;x 14.4.69 fcfie; 5$93 f;ZXh Gosh Direct 15-03-1996 15.3.96 18-03-1996 18.3.96 qwrwgVH gurdwspur phH;hH BC CF 595 CF SC1990 778 ;toB f;x $ nwho uzd 10.4.55 gzikph f;ZXh Gosh Direct 13-05-1996 13.5.96 15-05-1996 15.5.96 swieMs Xuint cMfIgVH cMfIgVH n?;H;hH SC CF 5971991 779 :kdftzdo f;x $ ifszdo f;zx 2.11.66 fj;kp 3$91 f;ZXh Gosh Direct 15-05-1996 15.5.96 01-06-1996 1.6.96 Dnolw iBob Gen1992 780 f;zrkok f;zx $ ;kX{ f;x 28.4.66 ewo; 4$89 f;ZXh Gosh Direct 20-05-1996 20.5.96 01-06-1996 1.6.96 rUp klW iBob Gen1993 781 ofizdo f;zx $ r[ow/b f;x 15.8.70 noE ;ak;aso 12$93 f;ZXh Gosh Direct 27-05-1996 27.5.96 28-05-1996 28.5.96 pitAwlw pitAwlw n?;H;hH SC RP1994 1213 ofizdo f;zx $ wkB f;zx (j/vhe/gN) 1.11.67 fcfie; 4$96 soZeh okjh Pro 28-08-1996 28.8.96 20-09-1996 20.9.96 nUrpur bydI ropV iBob Gen1995 782 fpz;a[po dk; $ wzrs okw 4.4.51 ewo; 6$89 f;ZXh Gosh Direct 06-11-1996 6.11.96 12-12-1996 12.12.96 roSnpur phH;hH BC CF 6151996 783 jofizdo f;x $ i'ok f;x 18.7.66 fJfsjk; f;ZXh Gosh Direct 18-11-1996 18.11.96 06-12-1996 6.12.96 ku`tI iBob Gen1997 784 sfizdo f;zx $ BZEk okw 1.9.65 fJfsjk; 4$91 f;ZXh Gosh Direct 18-11-1996 18.11.96 07-12-1996 7.12.96 bMgw nvWSihr iBob Gen1998 785 fBowb f;zx $ niw/o f;x 25.3.64 fJfsjk; 4$95 f;ZXh Gosh Direct 18-11-1996 18.11.96 27-11-1996 27.11.96 BweI rUpw biTMfw n?;H;hH SC RP1999 786 ;[ywzdo f;zx $ jofdnkb f;zx 12.4.70 fJfsjk; 9$95 - f;ZXh Gosh Direct 19-11-1996 19.11.96 09-01-1997 9.1.97 BwjBw n?;H;hH SC CF 6012000 787 joGiB f;zx $ do;aB f;x 14.12.68 g'b ;kfJz; 8$93- f;ZXh Gosh Direct 56.37 28-11-1996 28.11.96 13-12-1996 13.12.96 jMifAwlw gurU AimMRqsr n?;H;hH SC CF 6052001 788 fe;a'o e[wko $ eosko uzd 13.2.65 g'b ;kfJz; 7$90- f;ZXh Gosh Direct 56.21 28-11-1996 28.11.96 13-12-1996 13.12.96 Grotw phH;hH BC CF 6352002 789 ioB?b f;zx $ r[oBkw f;x 19.10.55 g'b ;kfJz; 8$84- f;ZXh Gosh Direct 56.2 28-11-1996 28.11.96 04-12-1996 4.12.96 kwrwnI KyVw n?;H;hH SC RP2003 790 r[ogqek;a fz;zx $ oDpho f;zx 4.12.68 g'b ;kfJz; 7$91 - f;ZXh Gosh Direct 51.24 28-11-1996 28.11.96 19-12-1996 19.12.96 Gumx purw n?;H;hH SC CF 6092004 791 gkb okw $ do;aB okw 24.4.55 g'b ;kfJz; 4$89- f;ZXh Gosh Direct 45.98 28-11-1996 28.11.96 13-12-1996 13.12.96 qwlq n?;H;hH SC CF 6132005 792 gqhsw f;x $ ;/tk f;zx 1.3.55 g'b ;kfJz; 3$83- f;ZXh Gosh Direct 59.23 28-11-1996 28.11.96 10-12-1996 10.12.96 sMDoV iBob Gen2006 793 r[oihs f;zx $ e[bdhg f;x 7.9.62 g'b ;kfJz; 8$83- f;ZXh Gosh Direct 59.14 28-11-1996 28.11.96 12-12-1996 12.12.96 lwj iBob Gen CF2007 794 ;aoB ihs f;zx $ fjzws f;x 10.1.67 g'b ;kfJz; 4$98- f;ZXh Gosh Direct 59.1 28-11-1996 28.11.96 17-12-1996 17.12.96 AnMdpur sihb ropV iBob Gen2008 795 ow/;a gkb $ shoE okw 1.3.59 g'b ;kfzJz; 4$85- f;ZXh Gosh Direct 58.94 28-11-1996 28.11.96 17-12-1996 17.12.96 jYTUvwl AimMRqsr iBob Gen CF BC2009 796 fti? ew[ko $ dohnk fds wZb 31.1.55 g'b ;kfJz; 9$84- f;ZXh Gosh Direct 57.67 28-11-1996 28.11.96 07-12-1996 7.12.96 ihMdBwl iBob Gen2010 797 r'gkb fe;qB $ jkew uzd 22.12.66 g'b ;kfJz; 9$90- f;ZXh Gosh Direct 57.43 28-11-1996 28.11.96 10-12-1996 10.12.96 p`KIklW iBob Gen CF52/82
TRIAL ID: PRIMA19 REFERENCES• Bordeleau L, Berinstein NL. Molecular diagnostics in follicular non-Hodgkin's lymphoma: a review. SeminOncol. 2000; 27 (Suppl 12):42-52.• Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, et al. Rituximab therapy inhaematologic malignancy patients with circulating blood tumor cells: association with increased infusionrelatedside effects and rapid blood tumor clearance. J Clin Oncol 1999; 17:791–5.• Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, and al. Report of an internationalworkshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999; 17:1244–53.• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G,Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared withCHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346:235-242• Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, and al. Rituximab (anti-CD20monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumorburden: clinical and molecular evaluation. Blood 2001; 97:101–106.• Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, and al. Treatment ofpatients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibodyand CHOP chemotherapy. J Clin Oncol 1999; 17:268–76.• Czuczman MS, Grillo-Lopez AJ LoBuglio AI, Gordon LI, Starostik P, Dowden S, Alkuzweny B, Allen RS.Patients with Low-Grade NHL Treated with Rituximab + CHOP Experience Prolonged Clinical andMolecular Remission. ASH 2003, abstract 1493.• Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME,Mohrbacher A, Weaver R, Dowden S, Levy R. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol. 1999; 17:1851-1857• Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J ClinOncol 2000; 18:3135–43.• Demidem A, Lam T, Alan S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8)monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. CancerBiotherapy and Radiopharmaceuticals 1997; 12:177-186.• Dreyling M, Forstpointner R, Repp R, Herrmann S, Haenel A, Metzner B, Pott C, Hartmann F, RothmannF, Parwaresch R, Unterhalt M, Hiddemann W. Combined immuno-chemotherapy (R-FCM) results insuperior remission and survival rates in recurrent follicular and mantle cell lymphoma - final results of aprospective randomized trial of the GLSG. Annual Meeting of the American Society of Haematology, SanDiego. Blood 102, No. 11: (2003)• Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, Malpas JS, Lister TA.Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986; 4:1470-80.• Ghielmini M, Hsu Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, BetticherDC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M,Vorobiof D, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantlyincreases event-free survival and response duration compared with the standard weekly x 4 schedule.Blood. 2004; 103:4416-4423• Gregory SA, Venugopal P, Adler S, Enschede S, Yunus F, O'Brien TM, O'Donnell KF, Robin EL.Combined Fludarabine, Mitoxantrone, and Rituximab Achieves a High Response as Initial Treatment forAdvanced Low Grade Non-Hodgkin's Lymphoma (LGNHL). Blood. 2002; 100:(abstr 1401).• Hainsworth JD, Burris III HA, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemictherapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000;95:3052-3056.• Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA.Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J ClinOncol. 2002; 20:4261-7.• Hainsworth JD, Litchy S, Greco FA. Scheduled Rituximab Maintenance Therapy Versus RituximabRetreatment at Progression in Patients with Indolent Non-Hodgkin's Lymphoma (NHL) Responding toSingle-Agent Rituximab: A Randomized Trial of the Minnie Pearl Cancer Research Network. ASH 2003,abstract 231.• Herold M, Dölken G, Fiedler F et al. Ongoing clinical studies – randomized phase III study for thetreatment of advanced indolent NHL and MCL:chemotherapy versus chemotherapy plus Rituximab. AnnHematol. 2003; 82:77–79.• Hiddemann W, Unterhalt M. Stand und Perspektiven in der Therapie follikulärer Keimzentrumslymphome.Dt Ärzteblatt 1998; 95:3209–3216.Version 5.1 – 4 December 2008 PRIMA protocol Page 53/74
Page 1 and 2: Tentative Seniority List of Lecture
Page 3 and 4: Seniority No.Roster ofDirectRecruit
Page 5 and 6: 01-10-2010Seniori Roster of Rosterp
Page 51: 01-10-2010Seniori Roster of Rosterp

Male Female Lec Seniority FINAL 1.10.10.xlsx - SSA Punjab

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?